Esophageal Adenocarcinoma Methods and Protocols

(sharon) #1
227

mous cell carcinomas and esophageal adenocar-
cinomas reveals similarities and differences.
Oncologist 20(10):1132–1139. https://doi.
org/10.1634/theoncologist.2015-0156


  1. Fecteau RE, Kong J, Kresak A, Brock W, Song
    Y, Fujioka H, Elston R, Willis JE, Lynch JP,
    Markowitz SD, Guda K, Chak A (2016)
    Association between germline mutation in
    VSIG10L and familial Barrett neoplasia. JAMA
    Oncol 2(10):1333–1339. https://doi.
    org/10.1001/jamaoncol.2016.2054

  2. Bian YS, Osterheld MC, Fontolliet C, Bosman
    FT, Benhattar J (2002) p16 inactivation by
    methylation of the CDKN2A promoter occurs
    early during neoplastic progression in Barrett’s
    esophagus. Gastroenterology
    122(4):1113–1121

  3. Silvers AL, Lin L, Bass AJ, Chen G, Wang Z,
    Thomas DG, Lin J, Giordano TJ, Orringer
    MB, Beer DG, Chang AC (2010) Decreased
    selenium-binding protein 1 in esophageal ade-
    nocarcinoma results from posttranscriptional
    and epigenetic regulation and affects chemo-
    sensitivity. Clin Cancer Res 16(7):2009–2021.
    https://doi.org/10.1158/1078-0432.
    ccr-09-2801

  4. Bian YS, Osterheld MC, Bosman FT, Benhattar
    J, Fontolliet C (2001) p53 gene mutation and
    protein accumulation during neoplastic pro-
    gression in Barrett’s esophagus. Mod Pathol
    14(5):397–403. https://doi.org/10.1038/
    modpathol.3880324

  5. Stachler MD, Taylor-Weiner A, Peng S,
    McKenna A, Agoston AT, Odze RD, Davison
    JM, Nason KS, Loda M, Leshchiner I, Stewart
    C, Stojanov P, Seepo S, Lawrence MS, Ferrer-
    Torres D, Lin J, Chang AC, Gabriel SB, Lander
    ES, Beer DG, Getz G, Carter SL, Bass AJ
    (2015) Paired exome analysis of Barrett’s
    esophagus and adenocarcinoma. Nat Genet
    47(9):1047–1055. https://doi.org/10.1038/
    ng.3343

  6. Dolan K, Walker SJ, Gosney J, Field JK, Sutton
    R (2003) TP53 mutations in malignant and
    premalignant Barrett’s esophagus. Dis
    Esophagus 16(2):83–89

  7. Doak SH, Jenkins GJ, Parry EM, Griffiths AP,
    Shah V, Baxter JN, Parry JM (2003)
    Characterisation of p53 status at the gene,
    chromosomal and protein levels in esophageal
    adenocarcinoma. Br J Cancer 89(9):1729–
    1735. https://doi.org/10.1038/sj.
    bjc.6601323

  8. Chung SM, Kao J, Hyjek E, Chen YT (2007)
    p53 in esophageal adenocarcinoma: a critical
    reassessment of mutation frequency and identi-
    fication of 72Arg as the dominant allele. Int
    J Oncol 31(6):1351–1355
    14. Novotna K, Trkova M, Pazdro A, Smejkal M,
    Soukupova A, Kodetova D, Smejkal P, Sedlacek
    Z (2006) TP53 gene mutations are rare in
    nondysplastic Barrett’s esophagus. Dig Dis Sci
    51(1):110–113. https://doi.org/10.1007/
    s10620-006-3093-3
    15. Del Portillo A, Lagana SM, Yao Y, Uehara T,
    Jhala N, Ganguly T, Nagy P, Gutierrez J,
    Luna A, Abrams J, Liu Y, Brand R, Sepulveda
    JL, Falk GW, Sepulveda AR (2015) Evaluation
    of mutational testing of preneoplastic Barrett’s
    mucosa by next-generation sequencing of for-
    malin-fixed, paraffin-embedded endoscopic
    samples for detection of concurrent dysplasia
    and adenocarcinoma in Barrett’s esophagus.
    J Mol Diagn 17(4):412–419. https://doi.
    org/10.1016/j.jmoldx.2015.02.006
    16. Galipeau PC, Li X, Blount PL, Maley CC,
    Sanchez CA, Odze RD, Ayub K, Rabinovitch
    PS, Vaughan TL, Reid BJ (2007) NSAIDs
    modulate CDKN2A, TP53, and DNA content
    risk for progression to esophageal adenocarci-
    noma. PLoS Med 4(2):e67. https://doi.
    org/10.1371/journal.pmed.0040067
    17. Madani K, Zhao R, Lim HJ, Casson AG (2010)
    Prognostic value of p53 mutations in esopha-
    geal adenocarcinoma: final results of a 15-year
    prospective study. Eur J Cardiothorac Surg
    37(6):1427–1432. https://doi.
    org/10.1016/j.ejcts.2009.12.018
    18. Casson AG, Evans SC, Gillis A, Porter GA,
    Veugelers P, Darnton SJ, Guernsey DL,
    Hainaut P (2003) Clinical implications of p53
    tumor suppressor gene mutation and protein
    expression in esophageal adenocarcinomas:
    results of a ten-year prospective study. J Thorac
    Cardiovasc Surg 125(5):1121–1131. https://
    doi.org/10.1067/mtc.2003.176
    19. Rajendra S, Wang B, Merrett N, Sharma P,
    Humphris J, Lee HC, Wu J (2016) Genomic
    analysis of HPV-positive versus HPV-negative
    esophageal adenocarcinoma identifies a differ-
    ential mutational landscape. J Med Genet
    53(4):227–231. https://doi.org/10.1136/
    jmedgenet-2015-103411
    20. Astori G, Merluzzi S, Arzese A, Brosolo P, de
    Pretis G, Maieron R, Pipan C, Botta GA (2001)
    Detection of human papillomavirus DNA and
    p53 gene mutations in esophageal cancer sam-
    ples and adjacent normal mucosa. Digestion
    64(1):9–14. https://doi.
    org/10.1159/000048834
    21. Wijnhoven BP, de Both NJ, van Dekken H,
    Tilanus HW, Dinjens WN (1999) E-cadherin
    gene mutations are rare in adenocarcinomas of
    the esophagus. Br J Cancer 80(10):1652–
    1657. https://doi.org/10.1038/sj.
    bjc.6690577


Single Gene Mutation in Esophageal Adenocarcinoma
Free download pdf